Guiding Treatment Decisions in Cancer using Protein Biomarker Measurements: from Design to Utility
Conference Recording Apr 30, 2013
About the SpeakerSteve is currently Professor of Proteomics and a Director of the Proteome Research Centre in the UCD Conway Institute of Biomolecular and Biomedical Research at University College Dublin. Steve graduated from Imperial College of Science and Technology (University of London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. During his PhD he was awarded an Elmore Medical Research Fellowship. It was during this fellowship that his interests in the regulation of the mammalian cell cycle began, the subject of his research that was continued when he moved to the University of Liverpool as a Wellcome Trust lecturer.
In Europe and the US, prostate cancer is the most common cancer diagnosis in men and the second most common cause of male cancer-related death. At present, serum prostate-specific antigen (PSA) is the only molecular biomarker widely used in the diagnosis and management of patients with prostate cancer. Disappointingly, PSA levels cannot distinguish indolent from aggressive disease warranting an urgent need to identify clinically relevant biomarkers that will improve the management and treatment of prostate cancer patients.
We have developed a gel and label-free LC-MS based ‘proteomic pipeline' for protein biomarker discovery using a ‘clinical question driven’ strategy. Candidate biomarkers have been assessed by feature selection and classification using a range of statistical methods and assembled into a panel. Currently, potential 'protein biomarker signatures' are being tested by multiple reaction monitoring (MRM) based simultaneous measurement of multiple candidate biomarkers from the panel with some success. The potential of this approach in advancing more patient tailored approaches for the delivery of personalised patient care for prostate cancer and other diseases will be discussed.